Edwards Lifesciences Corporation News
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
see moreEdwards Lifesciences Corporation Market News
1d
Edwards Lifesciences Secures FDA Approval for AUTUS Pediatric Pulmonary Valve
- Edwards Lifesciences won FDA approval for its AUTUS size‑adjustable surgical pulmonary valve for pediatric congenital heart disease on October 1, 2026 — a material medtech milestone.
8d
FTC Issues Proposed Final Judgment in Edwards Lifesciences Antitrust Case Over JC Medical Acquisition
The FTC’s proposed settlement requires Edwards to pay $10M and implement compliance measures over its 2024 JC Medical acquisition, per filings published this week.
15d
Edwards Lifesciences Poised for Upward Momentum as CMS TAVR Coverage Decision Nears
Edwards Lifesciences (EW) eyes potential stock catalyst this week as CMS finalizes its TAVR national coverage decision, with investor sentiment bolstered.
22d
CMS Expands Medicare Coverage for TAVR, Bolstering Edwards Lifesciences’ Growth Outlook
CMS’s recent decision to expand Medicare coverage for transcatheter aortic valve replacement (TAVR) to asymptomatic patients opens a potential $2 billion revenue runway for Edwards Lifesciences.
29d
Edwards Lifesciences’ Second‐Quarter Momentum Extended by Anticipated Medicare Coverage Decision and Regulatory Outlook
Edwards Lifesciences (EW) builds on its strong Q2 performance as the Centers for Medicare & Medicaid Services advances a pivotal coverage decision on TAVR, potentially broadening access and supporting growth.